Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Hereditary Spastic Paraplegia (SPG46) and Cerebellar Ataxia Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GBA2 drug discovery and selectivity profiling. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GBA2 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Ideal for biochemical selectivity assays. |
View GBA2 Products |
| Gene Delivery | GBA2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and genetic rescue studies in SPG46 models. |
View GBA2 Products |
| Benchmark Ab | Anti-GBA2 Recombinant Antibody Highly specific positive control for expression validation and Western Blot/IP assays. |
View GBA2 Products |
| Validator | GBA2 siRNA Set For target knockdown verification and functional specificity validation. |
View GBA2 Products |
| Related Target A | GBA1 (Lysosomal acid glucosylceramidase) Essential counter-screening target to ensure drug selectivity and avoid off-target lysosomal toxicity. |
View GBA1 Products |
| Related Target B | GBA3 (Cytosolic beta-glucosidase) Homologous neutral glucosidase used for comprehensive family-wide selectivity profiling. |
View GBA3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GBA1 vs. GBA2 Selectivity Profiling | Active recombinant GBA2 and GBA1 proteins available for parallel enzymatic inhibition assays. |
| Loss-of-Function Disease Modeling (SPG46) | High-titer Lentiviral vectors expressing wild-type GBA2 for rescue assays in patient-derived fibroblasts. |
| Lack of Validated Detection Antibodies | Sequence-defined recombinant antibodies ensuring batch-to-batch reproducibility without hybridoma drift. |
| Off-Target Screening of GBA1 Inhibitors | Validated GBA2 target reagents to counter-screen small molecule glucosylceramide synthase (GCS) inhibitors or GBA1 chaperones. |
Live GBA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape surrounding GBA2 (non-lysosomal glucosylceramidase) is distinct from its lysosomal counterpart, GBA1. While GBA1 mutations are famously linked to Gaucher disease and Parkinson's disease, loss-of-function mutations in GBA2 are the direct genetic cause of Hereditary Spastic Paraplegia type 46 (SPG46) and autosomal recessive cerebellar ataxia. Consequently, therapeutic strategies for GBA2 focus primarily on gene replacement therapy and the development of selective modulators.
Conversely, in the small molecule arena targeting GBA1 (such as pharmacological chaperones or substrate reduction therapies), GBA2 represents a critical counter-screening target. Off-target inhibition of GBA2 by non-selective GBA1 inhibitors (such as miglustat) is associated with undesirable side effects, including motor deficits and male infertility. Thus, achieving high selectivity for GBA1 over GBA2—or vice versa—is a primary objective in neurodegenerative drug discovery.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV/Lentivirus) | Academic Medical Centers, Biotech Startups | Hereditary Spastic Paraplegia (SPG46), Cerebellar Ataxia | Functional rescue assays (Need GBA2 Lentivirus for stable expression and pathway validation) |
| Small Molecule (Selective Inhibitors) | Pharmaceutical Innovators (GBA1/GBA2 programs) | Neurodegenerative Disorders, Glycolipid Storage Modulation | High-throughput enzymatic assays (Need active GBA2 vs. GBA1 recombinant proteins for selectivity screening) |
| RNA Therapeutics (siRNA/ASO) | Translational Research Consortia | Spasticity and Ataxia Disease Modeling | Target knockdown verification (Need sequence-verified GBA2 siRNA sets) |